Recombinant Human VEGFR-2/KDR/CD309 Protein
Sizes: 10ug, 20g, 50ug, 100ug
Catalogue Numbers: RP00084-10, RP00084-20, RP00084-50, RP00084-100
Citations, Manuals and MSDS Available upon request.
Description: Recombinant Human VEGFR-2/KDR/CD309 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Ala20-Glu764) of human VEGF R2/KDR (Accession #NP_002244.1) fused with a 6×His tag at the C-terminus.
Alternate Names: CD309, FLK1, VEGFR, VEGFR2, VEGF Receptor 2, KDR
SWISS: P35968
GeneID: 3791
Species: Human
Purity: ≥ 95 % as determined by SDS-PAGE.
Storage: Store at -20 ℃. Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.
Background: Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc. Mutations of this gene are implicated in infantile capillary hemangiomas.
Bio-Activity: 1.Measured by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells(HUVEC). The ED50 for this effect is typically 10-50 μg/mL in the presence of 10 ng/mL recombinant human VEGF165.|2.Measured by its binding ability in a functional ELISA. Immobilized PE anti-human CD309 (VEGFR2) Antibody at 1 μg/mL (25 μL/well) can bind Human VEGFR2 with a linear range of 0.46-68.8 ng/mL.
Source: HEK293 cells
Tag: C-His
Formulation: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. Contact us for customized product form or formulation.
Antigen Sequence: ASVGLPSVSLDLPRLSIQKDILTIKANTTLQITCRGQRDLDWLWPNNQSGSEQRVEVTECSDGLFCKTLTIPKVIGNDTGAYKCFYRETDLASVIYVYVQDYRSPFIASVSDQHGVVYITENKNKTVVIPCLGSISNLNVSLCARYPEKRFVPDGNRISWDSKKGFTIPSYMISYAGMVFCEAKINDESYQSIMYIVVVVGYRIYDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKPFVAFGSGMESLVEATVGERVRIPAKYLGYPPPEIKWYKNGIPLESNHTIKAGHVLTIMEVSERDTGNYTVILTNPISKEKQSHVVSLVVYVPPQIGEKSLISPVDSYQYGTTQTLTCTVYAIPPPHHIHWYWQLEEECANEPSQAVSVTNPYPCEEWRSVEDFQGGNKIEVNKNQFALIEGKNKTVSTLVIQAANVSALYKCEAVNKVGRGERVISFHVTRGPEITLQPDMQPTEQESVSLWCTADRSTFENLTWYKLGPQPLPIHVGELPTPVCKNLDTLWKLNATMFSNSTNDILIMELKNASLQDQGDYVCLAQDRKTKKRHCVVRQLTVLERVAPTITGNLENQTTSIGESIEVSCTASGNPPPQIMWFKDNETLVEDSGIVLKDGNRNLTIRRVRKEDEGLYTCQACSVLGCAKVEAFFIIEGAQEKTNLE
Endotoxin: < 0.1 EU/μg of the protein by LAL method.
Research Use Only